Tenderwize
Back to tender search

Open House Original Rebate Contracts 2026-02 - Ponatinib

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2028 · 620 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-02 - Ponatinib

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No estimated contract value or volume disclosed; potential low revenue.

Contract automatically ends upon patent expiry, shortening the effective period.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclude discount agreements for Ponatinib with all eligible pharmaceutical entrepreneurs.
  • Participants offer Ponatinib at discounted prices to the health insurance funds.
Show full summary

This is an Open House procedure for discount agreements (Rabattverträge) for the pharmaceutical product Ponatinib, organized by multiple German health insurance funds led by Techniker Krankenkasse. All eligible pharmaceutical entrepreneurs can join at any time during the contract period (May 2026 – April 2028). No competitive selection; contracts are concluded with all who meet the legal requirements. The estimated contract value is not disclosed, and no exclusivity is granted. The tender is not a public procurement under EU directives; disputes are subject to social court jurisdiction.

Risks

No estimated contract value or volume disclosed; potential low revenue.

Contract automatically ends upon patent expiry, shortening the effective period.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
  • Hold valid marketing authorization for Ponatinib in Germany/EU/EEA.

Eligibility

  • Submit self-declaration of eligibility and reliability (Anlage 4).

Requirements may be incomplete.

Award Criteria

Lot 1

Not specified; all eligible participants qualify.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Original Rebate Contracts 2026-02 - Ponatinib

Conclusion of pharmaceutical discount agreements for Ponatinib under §130c SGB V via an Open House procedure with uniform conditions; no individual negotiations; multiple participants allowed.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Apr 2026 - Apr 2028

Category

Pharmaceutical products

Award Criteria

Not specified; all eligible participants qualify.

Deadline

Deadline Apr 29, 2028

Procurement Details

Publication date
15 Mar 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
178647-2026

Documents (1)

Similar tenders